GOLGA6A-D Inhibitors
GOLGA6A-D inhibitors encompass a diverse range of chemical compounds that impact various cellular mechanisms leading to the downregulation of GOLGA6A-D activity. Wortmannin and Brefeldin A are prominent examples, where Wortmannin's inhibition of PI3K activity leads to a subsequent decrease in AKT signaling that is crucial for Golgi apparatus function, thereby indirectly affecting GOLGA6A-D. Brefeldin A's mechanism is different; it disrupts the Golgi structure by inhibiting ARF, which is essential for vesicle formation, and this disturbance in Golgi organization can result in an indirect inhibition of GOLGA6A-D. Similarly, the inhibition of dynamin by Dynasore and GBF1 by Golgicide A disrupts key trafficking events and Golgi structure maintenance, respectively, revealing how intracellular transport processes are crucial for GOLGA6A-D functionality. Monensin's alteration of intracellular pH and cation homeostasis leads to Golgi dysfunction, and as GOLGA6A-D is implicated in Golgi processes, its activity is consequently hindered. Nocodazole and Vinblastine impact microtubule dynamics, which are integral to Golgi positioning and function, thereby indirectly reducing GOLGA6A-D activity due to the disruption of this cellular framework.
The manipulation of the cytoskeleton also plays a significant role in the inhibition of GOLGA6A-D, as demonstrated by Cytochalasin D, which compromises actin filament formation and thereby potentially impairs GOLGA6A-D associated with the Golgi apparatus. Tunicamycin introduces ER stress by blocking N-linked glycosylation, which can cascade down to the Golgi apparatus, impacting GOLGA6A-D's role in its functioning. Ilomastat's inhibition of extracellular matrix remodeling can perturb cellular signaling, indirectly influencing GOLGA6A-D. Moreover, Betulinic Acid and Swainsonine target apoptosis and glycoprotein processing within the Golgi, respectively, which can lead to a breakdown in Golgi structure and function, and by extension, an indirect inhibition of GOLGA6A-D activity. Each of these inhibitors, through their specific actions on different pathways and cellular structures, contributes to the overall reduction in GOLGA6A-D functionality by interrupting the delicate balance of processes it is involved in.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it can prevent the downstream activation of AKT, which is involved in the regulation of Golgi apparatus and membrane trafficking. This could indirectly lead to the inhibition of GOLGA6A-D, which is associated with Golgi dynamics and function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi structure by inhibiting ADP-ribosylation factor (ARF), a small GTPase essential for vesicle formation from the Golgi. Inhibition of ARF by Brefeldin A could indirectly affect GOLGA6A-D function by destabilizing Golgi apparatus architecture. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor for dynamin, which is involved in membrane fission events such as vesicle scission from the Golgi. Inhibition of dynamin can indirectly affect the function of GOLGA6A-D by perturbing vesicle trafficking pathways. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1, which is critical for maintaining Golgi structure. Inhibition of GBF1 could indirectly impair GOLGA6A-D's role in Golgi apparatus function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a carboxylic ionophore that disrupts the Golgi function by altering intracellular pH and cation homeostasis, which could indirectly lead to the functional inhibition of GOLGA6A-D due to its role in Golgi maintenance. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent which can disrupt the microtubule network, essential for Golgi apparatus positioning and function. This disruption can lead to an indirect inhibition of GOLGA6A-D, which is involved in the Golgi structure. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D is an actin polymerization inhibitor, affecting cytoskeletal dynamics. Since the integrity of the actin cytoskeleton is crucial for Golgi apparatus function, this could indirectly influence GOLGA6A-D activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, leading to ER stress and potentially impacting Golgi function. As GOLGA6A-D is involved in Golgi apparatus processes, such ER stress could indirectly inhibit its activity. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine is an alkaloid that can disrupt microtubule assembly. The destabilization of microtubules can lead to an indirect inhibition of GOLGA6A-D by impacting Golgi apparatus function and vesicle transport. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
Ilomastat is a matrix metalloproteinase inhibitor that can affect the extracellular matrix remodeling, which may impact cellular signaling and indirectly influence GOLGA6A-D's role in Golgi apparatus maintenance. | ||||||